Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system

Japanese Journal of Clinical Oncology

Volumn 38, Issue 7, 2008, Pages 486-492

  Yasuda, Koichi ^a   Taguchi, Hiroshi ^a   Sawamura, Yutaka ^a   Ikeda, Jun ^a   Aoyama, Hidefumi ^a   Fujieda, Kenji ^a   Ishii, Nobuaki ^a   Kashiwamura, Masaaki ^a   Iwasaki, Yoshinobu ^a   Shirato, Hiroki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Late effect; Medulloblastoma; Primitive neuroectodermal tumor; Radiotherapy

Indexed keywords

CISPLATIN; CORTICOSTEROID; ETOPOSIDE; GONADOTROPIN; GROWTH HORMONE; IFOSFAMIDE; THYROID HORMONE; VASOPRESSIN;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRANIOSPINAL IRRADIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMANGIOMA; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INFANT; INTELLIGENCE QUOTIENT; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NEUROSURGERY; OVERALL SURVIVAL; PARTIAL BODY RADIATION; RADIATION DOSE; THERAPY EFFECT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INFANT; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RADIOTHERAPY DOSAGE; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 48849095646     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn049     Document Type: Article

References (32)

1. Freeman CR, Taylor RE, Kortmann R, Carrie C. Radiotherapy for medulloblastoma in children: A perspective on current international clinical research efforts. Med Pediatr Oncol 2002;39:99-108.
2. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J Clin Oncol 2003;21: 1581-91.
3. Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003;97:663-73.
4. Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brouwn J, et al. Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78.
5. Thomas PRM, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, et al. Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004-11.
6. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 1999;17:2127-36.
7. Kühl J, Müller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: Results of the German pilot trial HIT '88/'89. Klin Padiatr 1998;210:227-33.
8. Gentet JC, Bouffet E, Doz F, Tron P, Roche H, Thyss A, et al. Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: Results of the M7 French Cooperative Study. J Neurosurg 1995;82:608-14.
9. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993;3:255-68.
10. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial. J Clin Oncol. 1995;13:1687-96.
11. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000;88:2189-93.
12. Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, et al. Analysis of patients with supratentorial primitive neuroectodermal tumors entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer. 2006;42:1120-8.
13. Allen JC, Donahue B, DaRosso R, Nirenberg A. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys. 1996;36:1155-61.
14. Prados MD, Edwards MS, Chang SM, Russo C, Davis R, Rabbitt J, et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: Results of a Phase II study. Int J Radiat Oncol Biol Phys. 1999;43:279-85.
15. Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-9.
16. Sawamura Y, Ikeda J, Ishii N, Kato T, Tada M, Abe H, et al. Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor - results of a pilot study-. Neurol Med Chir (Tokyo) 1996;36:632-8.
17. Laurent JP, Chang CH, Cohen ME. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Cancer 1985;56:1807-9.
18. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45.
19. Packer RJ, Gajjar A, Vezina G, Adams LR, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-8.
20. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-20.
21. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005;23:5511-9.
22. Goldwein JW, Radcliffe J, Johnson J, Moshang T, Packer RJ, Sutton LN, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899-904.
23. Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;60:531-6.
24. Ris MD, Packer R, Goldwein J, Janes-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group Study. J Clin Oncol 2001;19:3470-6.
25. Palmer SL, Goloubeva O, Reddick WE, Glass JO, Gajjar A, Kun L, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 2001;19: 2302-8.
26. Grill J, Renaux VK, Bulteau C, Viguier D, Piebois CL, Rose CS, et al. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999;45:137-45.
27. Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: A French Society of Pediatric Oncology Study. J Clin Oncol 2005;23:4726-34.
28. Fukunaga-Johnson N, Sandler HM, Marsh R, Martel MK. The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int J Radiat Oncol Biol Phys 1998;41:77-82.
29. Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002;52:599-605.
30. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 2002; 415:436-42.
31. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93.
32. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: Results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007;13:2651-7.